NYU Langone Health Study Shows Melanoma Vaccine Sustains 49% Reduction in Recurrence Risk After 5 Years

A study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has shown that a personalized mRNA vaccine, intismeran, in combination with the immunotherapy pembrolizumab, reduced the risk of melanoma recurrence or death by 49% after five years of follow-up. The results of this phase 2b trial are being presented at the 2026 annual meeting of the American Society of Clinical Oncology and simultaneously published in the Journal of Clinical Oncology. [cite: 3 in previous search]